沙利度胺治疗可下调多发性骨髓瘤患者中SDF-1α和CXCR4的表达。

Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.

作者信息

Oliveira Adriana Morgan, Maria Durvanei Augusto, Metzger Martin, Linardi Camila, Giorgi Ricardo Rodrigues, Moura Fernanda, Martinez Gracia Aparecida, Bydlowski Sérgio Paulo, Novak Estela Maria

机构信息

Laboratory of Genetics and Molecular Hematology - LIM-31, Medical School, Universidade de São Paulo, USP, 05403-000 São Paulo, Brazil.

出版信息

Leuk Res. 2009 Jul;33(7):970-3. doi: 10.1016/j.leukres.2008.09.018. Epub 2008 Oct 30.

DOI:10.1016/j.leukres.2008.09.018

PMID:18976811

Abstract

The chemokine stromal-derived factor-1alpha (SDF-1alpha) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple myeloma. Here, we show that the expression of SDF-1alpha and CXCR4 was significantly down-regulated in patients treated with thalidomide (n=10) as compared to newly diagnosed MM patients (n=31) and MM patients treated with other drugs (n=38). SDF-1 alpha and CXCR4 expression was also significantly decreased in a RPMI 8226 cell line treated with 10 and 20micromol/L of thalidomide. Our findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1alpha in multiple myeloma.

摘要

趋化因子基质细胞衍生因子-1α（SDF-1α）及其受体CXCR4在多发性骨髓瘤中对浆细胞的定向迁移和归巢起着关键作用。在此，我们发现，与新诊断的骨髓瘤患者（n = 31）和接受其他药物治疗的骨髓瘤患者（n = 38）相比，接受沙利度胺治疗的患者（n = 10）中SDF-1α和CXCR4的表达显著下调。在用10和20微摩尔/升沙利度胺处理的RPMI 8226细胞系中，SDF-1α和CXCR4表达也显著降低。我们的研究结果表明，沙利度胺治疗可诱导多发性骨髓瘤中CXCR4及其配体SDF-1α的下调。